Clinical Trial Detail

NCT ID NCT03517969
Title ATR Kinase Inhibitor VX-970 and Carboplatin With or Without Docetaxel in Treating Participants With Metastatic Castration-Resistant Prostate Cancer
Recruitment Suspended
Gender male
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

prostate cancer

Therapies

Carboplatin + Docetaxel

Berzosertib + Carboplatin

Age Groups: senior adult

No variant requirements are available.